Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sugemalimab - CStone Pharmaceuticals/EQRx

Next Previous
Drug Profile

Sugemalimab - CStone Pharmaceuticals/EQRx

Alternative Names: Cejemly; CS-1001; Sugelimab; WBP-3155; Zegema; Zegemet; Zegemex; ZEJIEMEI

Latest Information Update: 18 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CStone Pharmaceuticals
  • Developer Bayer; CStone Pharmaceuticals; EQRx
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Extranodal NK-T-cell lymphoma; Non-small cell lung cancer; Squamous cell cancer
  • Phase III T-cell lymphoma
  • Phase II Hodgkin's disease
  • Phase I/II Liver cancer; Solid tumours
  • No development reported Small cell lung cancer

Most Recent Events

  • 27 Mar 2025 CStone pharmaceuticals submits a new indication application for sugemalimab for the treatment of phase III Non-small cell lung cancer to the European Medicines Agency (EMA)
  • 23 Mar 2025 Preregistration for Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable, First-line therapy) in European Union (IV)
  • 28 Feb 2025 The European Society for Medical Oncology Dynamic Clinical Guidelines for non-driver positive metastatic non-small cell lung cancer recommends sugemalimab as first-line therapy for Non-small cell lung cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top